Belite Bio Raises $350 Million to Advance Retinal Disease Therapies Toward Commercialization
核心洞察
Belite Bio (搜索) priced a $350 million public offering at $154 per American Depositary Share to fund commercialization preparation and pipeline expansion.
The company is developing Tinlarebant, an oral therapy targeting degenerative retinal diseases including Stargardt disease and geographic atrophy (搜索).
Tinlarebant has completed Phase 3 trials in adolescent Stargardt disease patients and is currently in Phase 3 testing for geographic atrophy (搜索).
Belite Bio (搜索), a clinical-stage biotechnology company developing treatments for degenerative retinal diseases, announced the pricing of a $350 million public offering on December 1, 2025. The company priced 2,272,727 American Depositary Shares at $154.00 per share, with underwriters granted a 30-day option to purchase an additional 340,909 shares.
The substantial funding round positions Belite Bio (搜索) to advance its lead therapeutic candidate, Tinlarebant, toward potential commercialization while expanding its pipeline of treatments for rare retinal conditions with significant unmet medical needs.
Clinical Pipeline Progress
Belite Bio (搜索)'s primary focus centers on Tinlarebant, an oral therapy designed to reduce the accumulation of bisretinoid toxins (搜索) in the eye. The drug candidate has demonstrated clinical progress across multiple indications, having completed a Phase 3 trial called DRAGON in adolescent patients with Stargardt disease type 1 (搜索) (STGD1).
The company is currently conducting two additional pivotal studies: DRAGON II, a Phase 2/3 trial in adolescent STGD1 subjects, and PHOENIX, a Phase 3 trial evaluating Tinlarebant in patients with geographic atrophy (搜索) (GA) associated with advanced dry age-related macular degeneration (搜索).
Strategic Use of Capital
Belite Bio (搜索) outlined three primary areas for deploying the net proceeds from the offering. The company plans to invest significantly in commercialization preparation, including building an in-house commercialization team, establishing sales networks and systems, and preparing for commercial manufacturing of future approved products.
Additional funding will support the development and expansion of the company's therapeutic pipelines, while a portion will be allocated to working capital and general corporate purposes. This strategic allocation reflects the company's transition from pure clinical development toward potential market readiness.
Market Position in Retinal Diseases
The company targets degenerative retinal diseases that represent areas of significant unmet medical need. Stargardt disease type 1 (搜索) affects young patients and leads to progressive vision loss, while geographic atrophy (搜索) represents an advanced form of dry age-related macular degeneration (搜索) that can cause severe visual impairment.
Belite Bio (搜索)'s approach focuses on addressing the underlying pathophysiology of these conditions through the reduction of toxic bisretinoid accumulation, potentially offering a disease-modifying treatment approach for patients with limited therapeutic options.
Financial Structure and Timeline
The public offering involves major financial institutions as underwriters, with Morgan Stanley (搜索), Leerink Partners (搜索), BofA Securities (搜索), and Cantor serving as joint active book-running managers. H.C. Wainwright acts as lead manager, while Maxim Group and Titan Partners Group serve as co-managers.
The offering is expected to close on or about December 3, 2025, subject to customary closing conditions. The transaction is being conducted under Belite Bio (搜索)'s existing registration statement on Form F-3ASR, which became automatically effective in January 2025.